KR20240142564A - 생산물 정제 방법 - Google Patents

생산물 정제 방법 Download PDF

Info

Publication number
KR20240142564A
KR20240142564A KR1020247030267A KR20247030267A KR20240142564A KR 20240142564 A KR20240142564 A KR 20240142564A KR 1020247030267 A KR1020247030267 A KR 1020247030267A KR 20247030267 A KR20247030267 A KR 20247030267A KR 20240142564 A KR20240142564 A KR 20240142564A
Authority
KR
South Korea
Prior art keywords
protein
antibody
washing
interest
affinity chromatography
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247030267A
Other languages
English (en)
Korean (ko)
Inventor
안드레아스 세바스티안 추어브리겐
캐롤 인-알본
Original Assignee
코디악 사이언시스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코디악 사이언시스 인코포레이티드 filed Critical 코디악 사이언시스 인코포레이티드
Publication of KR20240142564A publication Critical patent/KR20240142564A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247030267A 2022-02-10 2023-02-09 생산물 정제 방법 Pending KR20240142564A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263267810P 2022-02-10 2022-02-10
US63/267,810 2022-02-10
PCT/US2023/062322 WO2023154822A2 (en) 2022-02-10 2023-02-09 Methods of purifying a product

Publications (1)

Publication Number Publication Date
KR20240142564A true KR20240142564A (ko) 2024-09-30

Family

ID=87521638

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247030267A Pending KR20240142564A (ko) 2022-02-10 2023-02-09 생산물 정제 방법

Country Status (10)

Country Link
US (1) US20230250133A1 (enExample)
EP (1) EP4476237A2 (enExample)
JP (1) JP2025505696A (enExample)
KR (1) KR20240142564A (enExample)
CN (1) CN119032099A (enExample)
AU (1) AU2023217074A1 (enExample)
CA (1) CA3251000A1 (enExample)
IL (1) IL314472A (enExample)
MX (1) MX2024009755A (enExample)
WO (1) WO2023154822A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2025073922A1 (en) * 2023-10-04 2025-04-10 Sartorius Bia Separations D.O.O. Enhanced chromatographic separations of components in a mixture by employing chaotropic elution
WO2025184423A1 (en) * 2024-02-29 2025-09-04 Kodiak Sciences Inc. Cell-surface-targeting-domain-polymer-payload conjugate
US20260092109A1 (en) * 2024-09-06 2026-04-02 Eyebiotech Limited Multivalent fzd4, wnt co-receptor, and vegf receptor molecules and uses thereof
US20260092125A1 (en) * 2024-09-06 2026-04-02 Eyebiotech Limited Multivalent fzd4, wnt co-receptor, and vegf binding molecules and uses thereof
WO2026075981A1 (en) * 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Methods of analyzing heterodimeric proteins
CN119524125A (zh) * 2024-11-28 2025-02-28 北海康成(苏州)生物制药有限公司 一种欧莫扑拜单抗原液的生产方法及欧莫扑拜单抗原液
CN119454939A (zh) * 2024-11-28 2025-02-18 北海康成(苏州)生物制药有限公司 一种欧莫扑拜单抗原液及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045314B2 (en) * 2000-04-04 2006-05-16 Baxter International Inc. Method for the production of bacterial toxins
RU2011137030A (ru) * 2009-03-11 2013-04-20 УАЙТ ЭлЭлСи Способы очистки малых модулярных иммунофармацевтических белков
AU2012328880B2 (en) * 2011-10-24 2017-02-23 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
ES2895752T3 (es) * 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
BR112016014969A2 (pt) * 2014-01-15 2018-01-23 Hoffmann La Roche polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
JP6959912B2 (ja) * 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
KR20250057128A (ko) * 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US12071476B2 (en) * 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US20210254073A1 (en) * 2020-02-04 2021-08-19 Cornell University Methods for capture and analysis of macromolecular complexes

Also Published As

Publication number Publication date
CA3251000A1 (en) 2023-08-17
WO2023154822A3 (en) 2023-09-21
IL314472A (en) 2024-09-01
WO2023154822A2 (en) 2023-08-17
MX2024009755A (es) 2024-08-20
EP4476237A2 (en) 2024-12-18
WO2023154822A8 (en) 2024-04-04
AU2023217074A1 (en) 2024-08-15
US20230250133A1 (en) 2023-08-10
JP2025505696A (ja) 2025-02-28
CN119032099A (zh) 2024-11-26

Similar Documents

Publication Publication Date Title
JP7414371B2 (ja) 抗体および抗体複合体
US20230250133A1 (en) Methods of purifying a product
AU2015279560B2 (en) Dual PDGF/VEGF antagonists
US20240084043A1 (en) Methods of treating an eye disorder
AU2020265568B2 (en) Biparatopic FR-alpha antibodies and immunoconjugates
EP4724482A2 (en) Methods for analyzing mixed compositions of protein and protein conjugates
AU2024286366A9 (en) Compositions of conjugated and unconjugated proteins

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000